IQVIA Holdings Inc. (NYSE:IQV) Q1 2024 Earnings Call Transcript
Yahoo FinanceMay 4 09:27 ET
Form 144 | Laboratory Corp of America(LH.US) Director Proposes to Sell 100.18K in Common Stocks
SEC FILLINGS DISCLOSED/ May 3, $Laboratory Corp of America(LH.US)$ Director KERRII B ANDERSON intends to sell 500 shares of its common stock on May 3, with a total market value of approximately $100.1
moomoo NewsMay 3 17:25 ET
Health Care Climbs as Amgen Surges on Obesity-Drug Plans - Health Care Roundup
Health-care companies rose after a surprising new entrant in the obesity-drug bonanza from one biotech giant. Amgen shares surged after the biotech giant said it saw encouraging signs from its inject
Dow JonesMay 3 16:51 ET
IQVIA Holdings Price Target Cut to $250.00/Share From $275.00 by Evercore ISI Group
IQVIA Holdings Price Target Cut to $250.00/Share From $275.00 by Evercore ISI Group
Dow JonesMay 3 12:26 ET
Top Midday Stories: Apple's Dividend, Buybacks Announcements; Amgen Obesity Drug Trial Results; Exxon Completes Pioneer Acquisition
Wall Street's major indexes all jumped on the heels of a softer-than-expected jobs report released Friday by the US Department of Labor. In company news, Apple (AAPL) reported fiscal Q2 diluted earnin
MT NewswiresMay 3 12:14 ET
Catalent, Novo Nordisk Antitrust Review Extended by FTC
Catalent (CTLT) said Friday the US Federal Trade Commission is asking for more information while the agency reviews the proposed acquisition of the biologics and gene therapies company by Danish drug
MT NewswiresMay 3 10:12 ET
Here's Why IQVIA Holdings (IQV) Is a Strong Value Stock
Yahoo FinanceMay 3 09:40 ET
Forecasting The Future: 8 Analyst Projections For IQVIA Hldgs
Across the recent three months, 8 analysts have shared their insights on IQVIA Hldgs (NYSE:IQV), expressing a variety of opinions spanning from bullish to bearish.The table below summarizes their rece
BenzingaMay 3 09:01 ET
UPDATE 1-US FTC Seeks More Information on Novo Nordisk Parent-Catalent Deal
Yahoo FinanceMay 3 08:36 ET
Buy Rating Affirmed for IQVIA Holdings Amidst Strong Growth and Resilient Demand
TipRanksMay 3 08:16 ET
Leerink Partners Adjusts Price Target on IQVIA to $278 From $290
IQVIA Holdings (IQV) has an average rating of outperform and price targets ranging from $250 to $300, according to analysts polled by Capital IQ.
MT NewswiresMay 3 08:11 ET
Express News | Catalent Inc - Catalent and Novo Holdings Expect to Close Merger Towards End of Calendar Year 2024
ReutersMay 3 08:06 ET
Express News | Catalent Inc - Intend to Continue to Cooperate With FTC in an Effort to Obtain Antitrust Regulatory Clearance for Merger as Expeditiously as Possible
ReutersMay 3 08:05 ET
Express News | Catalent Inc - Catalent and Novo Nordisk Foundation Are in Process of Gathering Information and Documentary Materials Responsive to Second Request
ReutersMay 3 08:05 ET
Express News | Catalent Inc - Second Request Was Issued Under Notification Requirements of Hart-Scott-Rodino Antitrust Improvements Act of 1976, as Amended
ReutersMay 3 08:05 ET
Express News | Catalent-on May 2,Co,Novo Nordisk Foundation Each Received Request for Additional Information,Documentary Materials From FTC in Connection With Merger
ReutersMay 3 08:04 ET
IQVIA Holdings (IQV) Receives a Buy From Truist Financial
TipRanksMay 3 07:45 ET
IQVIA Holdings Is Maintained at Neutral by Baird
IQVIA Holdings Is Maintained at Neutral by Baird
Dow JonesMay 3 07:10 ET
Express News | Baird Maintains Neutral on IQVIA Hldgs, Lowers Price Target to $245
BenzingaMay 3 07:00 ET
IQVIA Hldgs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 10.29% Baird $254 → $245 Maintains Neutral 02/27/2024 33.7% Truist Securities $286 → $297 Maint
BenzingaMay 3 06:59 ET